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Gastric cancermost common cancers worldwide, and there are clinical caveats in predicting
tumor response to chemotherapy. This study describes the construction of an in vitro pharmacogenomic
database, and the selection of genes associated with chemosensitivity in gastric cancer cell lines. Gene
expression and chemosensitivity databases were integrated using the Pearson correlation coefﬁcient to give
the GC-matrix. The 85 genes were selected that were commonly associated with chemosensitivity of the
major anticancer drugs. We then focused on the genes that were highly correlated with each speciﬁc drug.
Classiﬁcation of cell lines based on the set of genes associated with each drug was consistent with the
division into resistant or sensitive groups according to the chemosensitivity results. The GC-matrix of the
gastric cancer cell line database was used to identify different sets of chemosensitivity-related genes for
speciﬁc drugs or multiple drugs.
© 2008 Elsevier Inc. All rights reserved.IntroductionChemotherapy is one of the most important modalities of cancer
treatment, and many investigators have tried to improve its efﬁcacy
and reduce its toxicity. However, there is still insufﬁcient under-
standing of the targets of drug activity and individual variability of
patients. These limitations are in part due to a lack of effective
predictive markers for drug sensitivity or resistance, and the clinical
application of the few predictive markers that have been identiﬁed
is not successful [1–6]. A number of genes have been reported to
inﬂuence chemosensitivity. However, it is clear that the sensitivity
of cancer cells to particular anticancer drugs cannot be predicted by
a single factor, but is determined by many factors that inﬂuence
overall sensitivity. To establish the optimal prediction system, new
techniques are being applied to identify sets of chemosensitivity-
related genes that could pharmacogenomically characterize the
response of cancer cells to the particular anticancer drugs.
Gastric cancer is one of the most common cancers worldwide,
and being treated using many chemotherapeutic agents. Althoughlogy, Department of Internal
ege of Medicine, Seodaemun-
2 393 3652.
l rights reserved.advanced gastric cancer is generally less responsive to chemother-
apy, newly developed agents and combination chemotherapy have
improved tumor responses. Several studies have reported that
chemotherapy for gastric cancer increased not only the survival of
patients but also the quality of life [7–9]. However, there are still
clinical caveats in predicting tumor response in gastric cancer.
Microarray technology has been used to screen genes that are
associated with chemosensitivity in cancer cell lines [2–5]. This
technology has facilitated the analysis of genome-wide expression
proﬁles that can efﬁciently generate information on a large scale in
clinical or biological samples. More recently, spotted oligonucleotide
microarrays, with a 70-base length, are used in genome screening
instead of cDNA microarrays. This technology provides a high quality
result, avoid clone validation, tracking and maintenance, and
minimize cross-hybridization [10–16].
In this study, we constructed an in vitro G-matrix (gene
expression database) using 22K human oligo chips, and a C-matrix
(chemosensitivity database) from 13 gastric cancer cell lines treated
with 16 anticancer agents. To complete the pharmacogenomic
database, GC-matrixes were produced from integrating the G- and
C-matrices using the Pearson correlation coefﬁcient. The GC-matrix
was initially used to select common chemosensitivity-related genes,
then to identify genes that correlated strongly with the response to
single anticancer agent, which would be predictive markers of
chemosensitivity for each drug.
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Gene expression proﬁling of gastric cancer cell lines (G-matrix)
To investigate the genetic characteristics of each cell line, we
performed gene expression proﬁling of 13 gastric cancer cell lines
without drug treatment. A total of 17,015 genes that satisfy the NMP
100% among the 13 cell lines were selected for further analysis (G-
matrix, Supplementary data ﬁle 1). When unsupervised hierarchical
clustering was done using log2 (Red/Green) ratio, there was no
signiﬁcant grouping of cell lines based on anatomical origin or
ethnicity (Fig. 1a). Note that the triplicates of YCC-10 clustered tightly
together than any other cell lines.
Chemosensitivity proﬁling of gastric cancer cell lines (C-matrix)
Sixteen anticancer drugs were tested for growth inhibition in 13
gastric cancer cell lines. When unsupervised hierarchical clustering
was performed with C-matrix composed of mean centered log10IC50
(Fig. 1b, C-matrix, Supplementary data ﬁle 2), the drugs were
classiﬁed into several groups according to their mechanism of
action, including tubulin inhibitors (paclitaxel, docetaxel, vinblastin,Fig. 1. G- and C-matrices. (a) G-matrix: unsupervised hierarchical clustering of 13 gastric
triplicates of YCC-10 clustered tightly together and were well differentiated from even the
gastric cancer cell lines based on the log10IC50 of 16 drugs. The scale bar on the right side of
denotes low IC50 (sensitive). (c) Drug cluster of GC-matrix: unsupervised hierarchical clusand vincristine), topoisomerase I inhibitors (irinotecan and topote-
can), and DNA alkylators (carboplatin and cisplatin). Red denotes
high IC50 (resistant) and green denotes low IC50 (sensitive). As
expected, the IC50s of leucovorin and cyclophosphamide in all cell
lines were higher than the Cmax of each drug. In addition, the IC50s
of methotrexate were also higher than its Cmax (data not shown).
We observed that the clustering pattern of the 13 gastric cancer cell
lines was different from that of G-matrix, as the cell lines clustered
according to similarity of gene expression in the G-matrix, while
clusters were arranged by drug sensitivity in C-matrix.
Correlation between gene expression and chemosensitivity (GC-matrix)
To screen the genes associated with chemosensitivity, the two
databases for gene expression and chemosensitivity were inte-
grated into one database matrix (GC-matrix, Supplementary data
ﬁle 3) using the Pearson correlation coefﬁcient. Using the GC-
matrix, a hierarchical clustering was performed based on the
correlation between drug sensitivity and gene expression for each
drug (Fig. 1c). There were slight discrepancies in the clustering of
drugs in the GC-matrix compared to the C-matrix. For example, 5-
FU, one of the antimetabolites, was clustered with tubulincancer cell lines based on the log2(Red/Green) ratio of 17015 genes (NMP 100%). The
most closely related cell lines. (b) C-matrix: unsupervised hierarchical clustering of 13
treeview indicates relative drug sensitivity; red denotes high IC50 (resistant) and green
tering of 17015 genes and 16 drugs based on the Pearson correlation coef ﬁ cient.
Fig. 2. Genes associated with common chemosensitivity. (a) Unsupervised hierarchical clustering of 85 common chemosensitivity-related genes and 16 drugs using their Pearson
correlation coefﬁcient. Green represents negative correlation (chemo-sensitive), and red represents positive correlation (chemo-resistant). (b) Unsupervised hierarchical clustering
of 85 genes and 13 gastric cancer cell lines based on their log2(R/G) ratio. (c) Multidimensional scaling of the expression of 85 genes. Common chemo-resistant cell lines,-sensitive cell
lines, and intermediate cell lines were displayed in red, blue, and green circles, respectively.
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55J.-J. Jung et al. / Genomics 93 (2009) 52–61inhibitors in the C-matrix, but was correctly clustered with other
antimetabolites in the GC-matrix. However, the drugs remained
clustered based on their known mechanism of action, such as
topoisomerase I inhibitors, tubulin inhibitors, and antimetabolites.Fig. 3. Supervised hierarchical clustering with selected genes and gastric cancer cell lines a
(c) Paclitaxel (FDR=0). (d) Doxetaxel (FDR=0.0046). (e) 5-FU (FDR=0). (f) Doxorubicin (FDRGenes associated with common chemosensitivity
Using the GC-matrix, we identiﬁed 85 genes which had correlation
coefﬁcients over |0.40| in 11 of 16 anticancer drugs. These 85 genes arend their chemosensitivity patterns. (a) Cisplatin (FDR=0). (b) Irinotecan (FDR=0.139).
=0.19).
Fig. 3 (continued).
56 J.-J. Jung et al. / Genomics 93 (2009) 52–61presumed to be common chemosensitivity-related genes in gastric
cancer. Hierarchical clustering with these 85 genes and the anticancer
drugs showed negative correlation (chemo-sensitive) and positive
correlation (chemo-resistant) (Fig. 2a). Then, the expression patterns
of these genes were examined in the same order as in Fig 2a for the 13
gastric cancer cell lines, with green representing down-regulated
expression, and red representing up-regulated expression (Fig. 2b).
The expression patterns of the 85 genes largely classiﬁed the cell lines
into three groups, representing cell lines that are resistant, sensitive,
and of intermediate sensitivity, to multiple drugs. It represents that
genes with positive correlation were over-expressed in common
chemo-resistant cell lines, and negatively correlated genes were over-
expressed in common chemo-sensitive cell lines. We also performed
the multidimensional scaling (MDS) (Fig. 2c) with the expression of
the 85 genes, and conﬁrmed that the common chemo-resistant and
-sensitive cell lines were well separated.
Selection of genes associated with drug-speciﬁc chemosensitivity
Genes with a correlation coefﬁcient in the GCmatrix of ≥ |0.6| were
subjected to two-class SAM analysis with the gastric cancer cell lines
to identify genes that could classify the cell lines as chemo-resistant
or-sensitive for each drug. The hierarchical clustering represented
well-dichotomized genes that were strongly associated with chemo-
resistance or-sensitivity to speciﬁc drugs. First, we could not analyze
the cyclophosphamide, leucovorin, methotrexate, because the IC50s of
cell lines in these drugs were higher than their Cmax, as mentioned
above. Using this algorithm, we could select genes associated with
chemosensitivity for cisplatin, irinotecan, paclitaxel, docetaxel, 5-FU
and doxorubicin, commonly used in gastric cancer, with low false
discovery rate (FDR, 0–0.2) (Fig. 3a–f). Each FDR was determined by
SAM in the result of gene selection. Table 2 shows the top 20 ranked
genes associated with chemosensitivity for each drug. The results for
the remaining 7 drugs are summarized in Supplementary ﬁgure. All ofthe selected genes associated with drug-speciﬁc chemosensitivity are
listed in a Supplementary data ﬁle 4.
Microarray validation with quantitative RT-PCR
To validate the microarray results, RNA expression of randomly
selected 2 genes, SOX9 and PTGER2, was performed using qRT-PCR
analysis in the 13 gastric cancer cell lines. Microarray and qRT-PCR
data were well correlated to each other with the Pearson correlation
coefﬁcient of 0.92 and 0.69 in SOX9 and PTGER2, respectively (Fig. 4a).
Linear regression model also showed that these two types of
measurements had signiﬁcant relation, pb0.05 (Fig. 4a). In the
microarray data SOX9 and PTGER2 were selected as down-regulated
genes in resistant cell lines to gemcitabine and 5-FU, respectively, and
that were correctly conﬁrmed in qRT-PCR results (Fig. 4b).
Discussion
In this study we analyzed the gene expression proﬁles of 13 human
gastric cancer cell lines, and compared them to chemosensitivity data
from the same cell lines. Two similar studies have previously been
carried out using in vitro and in vivo animal model system [2,4]. Scherf
et al. constructed the ﬁrst pharmacogenomic database using 60 cell
lines, 118 drugs and 1376 genes [2]. However, our study has different
aims, namely to: 1) expand the number of genes to 17,000 for more
genome-wide evaluation, 2) focus on gastric cancer cell lines, and 3)
evaluate recently developed anticancer drugs which are commonly
used for gastric cancer in the clinic.
Few studies have investigated genes associated with multi-drug
chemosensitivity using anticancer agents currently used in gastric
cancer. Accordingly, we would like to select gene sets related to
chemosensitivity for a large number of anticancer agents. Clinically,
such genes may be used to identify patients who are refractory to
currently used drugs, and thus need to enter clinical trials with newly
Fig. 4. Microarray validation with quantitative RT-PCR. (a) Linear regression model for
microarray and qRT-PCR log2 ratio of SOX9 (upper) and PTGER2 (lower) genes in 13
gastric cancer cell lines. The regression formulas, R2 values and Pearson correlation
coefﬁcient (r) are shown on the left upper corner, and p-values for linear regression are
on the right lower corner of each panel. In the qRT-PCR result of PTGER2, gene
expression in SNU-1 cell line was not detected, so the linear regression was done with
12 cell lines. (b) Relative fold changes of SOX9 and PTGER2 between resistant and
sensitive groups to gemcitabine and 5-FU, respectively. The patterns of microarray and
qRT-PCR were well matched. a, sensitive cell lines. b, resistant cell lines.
Table 1
The 85 genes related to common chemosensitivity
Positively correlated genes Negatively correlated genes
GenBank no. Symbol GenBank no. Symbol
NM_015367 BCL2L13 NM_001643 APOA2
NM_024952 C14orf159 NM_020375 C12orf5
NM_017759 FLJ20309 NM_030568 KHDC1
NM_144600 C16orf63 NM_022102 CCDC90A
NM_022158 FN3K NM_019084 CCNJ
NM_005814 GPA33 NM_001799 CDK7
NM_000841 GRM4 NM_021195 CLDN6
NM_033445 HIST3H2A NM_018403 DCP1A
NM_032303 HSDL2 NM_022365 DNAJC1
NM_024013 IFNA1 NM_001387 DPYSL3
NM_016027 LACTB2 NM_005088 SFRS17A
NM_002969 MAPK12 NM_022336 EDAR
NM_005918 MDH2 NM_013241 FHOD1
NM_024060 AHNAK NM_025139 ARMC9
NM_022474 MPP5 NM_014366 GNL3
NM_002514 NOV NM_004832 GSTO1
NM_005047 PSMD5 NM_001524 HCRT
NM_002842 PTPRH NM_016185 HN1
NM_002888 RARRES1 NM_014804 KIAA0753
NM_014059 C13orf15 NM_012311 KIN
NM_017585 SLC2A6 NM_058169 LOH12CR1
NM_003098 SNTA1 NM_144565 DUOXA1
NM_020777 SORCS2 NM_017830 OCIAD1
NM_054114 TAGAP NM_022375 OCLM
NM_013259 TAGLN3 NM_020190 OLFML3
NM_003234 TFRC NM_148961 OTOS
NM_020131 UBQLN4 NM_006206 PDGFRA
NM_031407 HUWE1 NM_005777 RBM6
NM_032050 PATZ1 NM_013349 NENF
XM_096883 – NM_012244 SLC7A8
XM_040195 – NM_005985 SNAI1
XM_170868 – NM_003201 TFAM
XM_098154 – NM_033285 TP53INP1
XM_173309 – NM_032236 USP48
NM_020224 – NM_007268 VSIG4
XM_032852 – NM_144621 ZBTB8
XM_047287 – XM_060462 –
XM_113998 –
NM_032739 –
NM_032715 –
NM_005758 –
XM_173080 –
XM_113861 –
XM_092919 –
XM_047196 –
XM_066500 –
XM_171129 –
XM_059017 –
–:Unknown gene.
57J.-J. Jung et al. / Genomics 93 (2009) 52–61developed agents. Alternatively, we may select patients who could
beneﬁt from the narrow therapeutic window of current chemother-
apy, and for whom drugs with low toxicity can be the best choice.
For the selection of genes associated with common chemo-
resistance or -sensitivity, we selected genes with a correlation
coefﬁcient greater than |0.40| for 11 of 16 (≥70%) anticancer drugs,
and identiﬁed 85 genes (37 positively correlated and 48 negatively
correlated, Table 1). A correlation coefﬁcient of |0.40| was the value at
which we could ﬁnd reasonable number of chemosensitivity-related
genes. When we applied the grouping method of Staunton et al. [5],
cell lines with common resistance were positioned at the upper
outlier area of IC50±0.6 standard deviation, while sensitive cell lines
were positioned at the lower outlier (Supplementary Table 1). Because
we selected only genes with a relatively high correlation, some genes
previously identiﬁed as being associated with chemosensitivity but
which had a relatively low correlation, were not selected. We did,however, conﬁrm previously reported genes such as MAD2L1, TXN
and FAS, which showed a high correlation with the drugs studied.
Among them, MAD2 is known to be involved in cellular mitotic arrest,
and is associated with multi-drug resistance in gastric cancer [17–19].
We also found that MAD2L1 correlated negatively with most of anti-
tubule agents including etoposide, vinblastine, carboplatin, metho-
trexate, paclitaxel, and vincristine (r=−0.75, −0.52, −0.51, −0.42,
−0.39, and −0.37, respectively). In addition, as Pranav Sinha et al.,
reported that thioredoxin (TXN) was over-expressed in a multi-drug
resistant gastric cancer cell line [20], we found that TXN had positive
correlation with topotecan, irinotecan and cisplatin (r=0.65, 0.51 and
0.40, respectively). Over-expression of the FAS gene sensitized drug
resistant gastric cancer cells to chemotherapeutic drugs [21,22], and is
known to be associated with inrinotecan sensitivity [23,24]. In our
data, FAS had signiﬁcant negative correlations with irinotecan,
topotecan, mitomycin, and gemcitabine (r=−0.88, −0.80, −0.57 and
−0.41, respectively, Fig. 5). These results support the reliability of our
GC-matrix based pharmacogenomic database with much wider
Fig. 5. Relationship between FAS expression and chemosensitivity to irinotecan and
topotecan in gastric cancer cell lines. (a) Relationship between FAS and irinotecan
(−0.88 correlation coefﬁcient). (b) Relationship between FAS and topotecan (−0.80
correlation coefﬁcient).
58 J.-J. Jung et al. / Genomics 93 (2009) 52–61spectrum of chemo-sensitive or-resistant genes in more diverse
chemotherapeutic agents.
While selecting the chemosensitivity genes related to each speciﬁc
drug, we faced a problem that we couldn't select the genes with
simple SAM analysis only using G-matrix. It can be explained as there
are too many genes without inﬂuence on the chemosensitivity, those
noisy genes might disturb the SAM in selecting signiﬁcant genes. So,
we introduced the GC-matrix into the process of gene selection, and
could ﬁlter out the genes which had relatively low correlation
coefﬁcient than other genes. Finally, we could select the chemosensi-
tivity related genes with two step analysis method, GC-matrix and
SAM, differently from previous studies. We conﬁrmed previously
reported chemosensitivity genes encoding targets of anticancer drugs,
which had a moderate correlation coefﬁcient as in the previous
studies, such as TP with 5-FU (r=0.28), UPP1 with 5-FU (r=−0.34), and
TOP2A,-B with etoposide (r=−0.35, −0.37, respectively). In addition,
some genes with unknown function could be found to have similar
correlation coefﬁcients to those reported previously [4], e.g., FAM38A
with 5-FU (r=0.42) and HMGCL, HSD17B2 with cisplatin (r=−0.51,
0.49, respectively). In our study, we applied more strict criteria for
gene selection with higher correlation coefﬁcient more than |0.6|,
resulting in many novel genes. In the case of irinotecan, some genes
associated with apoptosis and cell cycle arrest were over-expressed
in sensitive cell lines, including FAS (r=−0.88), AIF-1 (r=−0.73),
FKBP1A (r=−0.66), TNFRSF1B (r=−0.64), EDAR (r=−0.61), and
BBC3 (r=−0.67). Interestingly, FAS (apoptosis), and AIF1 (cell
cycle arrest) were also strongly correlated with topotecan, a drug
with a similar mechanism of action as iritotecan, (r=−0.80, −0.75,
respectively).
Increased expression of thymidylate synthetase (TYMS), which
inactivates 5-FU to 5-ﬂuoro-dUMP, was reported to correlate withgastric cancer cell resistance to 5-FU [4,25,26]. In our study,
however, TYMS was not selected in the 5-FU related gene set and
the correlation coefﬁcient between TYMS and 5-FU was as low as
0.038. In tracking of this result, we found that all of the expression
of TYMS in 13 cell lines was similarly low regardless of 5-FU
chemosensitivity. Possible reasons might be considered as below; 1)
The overexpression of TYMS may be occurred after the drug
treatment, 2) The function of TYMS may be activated with other
5-FU related genes, 3) Relationship between TYMS and other genes
associated with leucovorin may inﬂuence the expression of TYMS,
and 4) When a mutation of TYMS is occurred, the expression of
TYMS may be over-expressed. We then, therefore, focused on the
245 selected genes that were associated with sensitivity to 5-FU
(Fig. 3e). Of these, only 15 genes had a positive correlation (Table 2),
and which were relatively over-expressed in 5-FU resistant cell
lines, suggesting the association with 5-FU resistance.
To evaluate another applicability of our pharmacogenomic data-
base, we compared the GC-matrix of similar anti-tubule agents,
paclitaxel and docetaxel. We identiﬁed independent sets of genes
associated with paclitaxel or docetaxel chemosensitivity, i.e., there
were no genes that were selected for both paclitaxel and docetaxel,
although the functions of selected genes were similar for the two
drugs (data not shown). For example, many genes related to cell
adhesion, cell proliferation and proteolysis were selected in both
drugs, although the speciﬁc genes were different. It suggested that the
drugs may have different mechanisms of action and providing a
possible explanation for the difference in efﬁcacy and toxicity
spectrum of these drugs. In this way, we can compare speciﬁc genes
associated with drugs that have similar mechanisms of action, or
drugs that are used for combination chemotherapy.
This study focused on the intrinsic susceptibility of gastric
cancer to various anticancer drugs with respect to potential
application as predictive markers before introducing chemotherapy.
Therefore, in contrast with several researches which used cancer
cell lines with acquired drug-resistance [27] or immediately
following drug treatment [28], we used untreated gastric cancer
cell lines. This is a ﬁrst report that revealed the relation between
genes and anticancer drugs currently used for gastric cancer via
high-throughput method.
We identiﬁed several sets of chemosensitivity-related genes for a
speciﬁc drug or multiple drugs based on the GC-matrix of a gastric
cancer cell line database. These genes may act as predictive markers
for chemosensitivity in chemo-naive gastric cancer patients following
functional analysis and clinical validation.
Materials and methods
Cell lines and culture
Two human gastric cancer cell lines, AGS and NCI-N87, were
obtained from the American Type Culture Collection (Rockville,
Maryland, USA). MKN-45 and the SNU-series (SNU-1, SNU-484)
were obtained from the Japanese Cancer Research Resources Bank
and Korean Cell Line Bank, respectively. Eight cell lines, YCC-1, YCC-2,
YCC-3, YCC-6, YCC-7, YCC-10, YCC-11 and YCC-16, were established
from Korean gastric cancer patients at the Cancer Metastasis Research
Center (CMRC, Yonsei University College of Medicine, Seoul, Korea).
Cells were cultured under conditions provided by the manufacturer,
and were incubated at 37 °C in a 5% CO2 humidiﬁed atmosphere and
the media replaced every 3 days.
RNA preparation
Total RNA was extracted from each cell line using TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer's
instructions. The Yonsei reference RNA (Cancer Metastasis Research
Table 2
The top ranked genes positively and negatively associated with drug speciﬁc chemosensitivity for 6 drugs
Cisplatin Irinotecan 5-FU Doxorubicin Paclitaxel Docetaxel
Symbol r Symbol r Symbol r Symbol r Symbol r Symbol r
INSL4 0.8415 – 0.7474 AURKA 0.7632 TAF7L 0.8077 – 0.8355 – 0.8485
AKAP8L 0.8409 PHKA1 0.7398 HIST1H2AM 0.7623 – 0.8063 INO80 0.8087 MGST2 0.8275
ZNF613 0.8243 – 0.7282 ASPM 0.7333 INHBB 0.7547 INPP4B 0.8002 – 0.8274
PPHLN1 0.8056 PHGDH 0.6883 DDX58 0.7105 TBX3 0.7406 STEAP4 0.7554 C14orf108 0.8102
DSC2 0.7924 PFN2 0.6799 PI3 0.7086 CD151 0.7323 BRE 0.7501 – 0.8074
NKAP 0.7913 ARHGEF10 0.657 TRIP10 0.6841 DNAJC11 0.7288 MTHFD1L 0.7501 SLC6A13 0.807
NIT1 0.7847 – 0.6444 DHRS2 0.6661 GBP1 0.7266 SH3TC2 0.7451 IGSF8 0.8042
HOXB5 0.7817 CTSL1 0.6419 IFI6 0.6621 BIRC2 0.7185 MRPL33 0.6923 DHRS1 0.801
C1orf177 0.7761 PYGL 0.6051 AXL 0.6602 TSPAN2 0.6996 PLD1 0.6786 – 0.7926
KLF12 0.7705 TNFRSF1B −0.6433 SLC39A1 0.6549 GPR175 0.6902 – 0.6707 – 0.7662
ALPL 0.7626 ARFGAP1 −0.644 ATP1A1 0.6469 BIRC3 0.6801 IFNGR1 0.6563 – 0.7656
HMX1 0.7624 DTNBP1 −0.6599 BAIAP2 0.6261 – 0.6729 TNFSF13B 0.6551 GFOD1 0.76
– 0.7566 ZNF232 −0.6612 TRIM29 0.6209 IRF1 0.6671 PDE9A 0.6376 C6orf192 0.7499
SARS 0.7557 FKBP1A −0.6647 THBS1 0.6208 PCDHB3 0.6635 CD302 0.63 FAM129B 0.7359
MERTK 0.7555 BBC3 −0.6684 OLR1 0.6206 HSPA1B 0.6631 NOV 0.6293 ABHD4 0.7338
NEU1 0.7535 C19orf53 −0.6693 – −0.7451 SH3GL3 0.6627 – 0.625 C14orf94 0.729
– 0.7521 – −0.673 LZTFL1 −0.7485 CCND3 0.6596 TTLL7 0.6246 RABGGTA 0.7194
MARS 0.7509 – −0.6922 DEFB119 −0.7495 ZC3HDC1 0.6579 PCDH7 0.6185 – 0.7149
CDC26 0.7489 LOC197336 −0.6936 SCYE1 −0.7504 UBA7 0.6564 LGALS3BP 0.6125 MYLIP 0.7101
– 0.7469 FLI1 −0.7005 TSG101 −0.7518 CBX6 0.6458 HERC6 0.6048 STXBP6 0.702
ACCN3 −0.7637 – −0.7011 – −0.7545 TFAP2B −0.6975 AFF3 −0.725 SDC3 −0.6777
MYBL1 −0.7665 ATP13A1 −0.7173 FLJ22318 −0.7575 – −0.6988 SERPINB6 −0.7289 MAP1LC3B −0.6778
– −0.7717 – −0.7194 LONP1 −0.7588 CASC1 −0.7064 CBX1 −0.7362 RAB28 −0.6851
KCNMA1 −0.7758 AIF1 −0.7281 – −0.7608 – −0.7113 – −0.7368 ZBTB12 −0.7007
– −0.7786 NMUR2 −0.7296 SENP6 −0.7636 – −0.7122 LIMS2 −0.7384 APOL3 −0.7082
BMP1 −0.7858 C1GALT1 −0.7319 ZNF277 −0.7674 ZNF589 −0.7168 GPC4 −0.7421 RBAK −0.7172
ASAH2 −0.7862 RFX1 −0.7338 PRPSAP1 −0.7693 – −0.7185 KIFAP3 −0.7543 MRPS6 −0.7186
CXCR4 −0.7864 HOXC5 −0.7481 FAM167B −0.7771 – −0.719 LTK −0.7612 CD68 −0.7258
OSR2 −0.7883 – −0.749 BPTF −0.7798 ZBTB25 −0.7234 DLEU2 −0.7616 – −0.741
PARP3 −0.7947 – −0.7587 HESX1 −0.7915 – −0.7387 – −0.7649 TRAPPC3 −0.7559
RBM30 −0.7972 – −0.7718 PTER −0.7928 BAZ2B −0.7396 LRP4 −0.7667 SLC5A3 −0.7661
KCNAB2 −0.8016 UGT2B4 −0.7761 AKR1A1 −0.7982 IGJ −0.7641 SMAD5 −0.7677 – −0.7698
– −0.8077 NFE2 −0.7819 ALOX15B −0.8079 ENOSF1 −0.7649 PNRC2 −0.7709 EPN2 −0.7793
Rgr −0.8112 IGHMBP2 −0.7915 – −0.8205 METTL4 −0.789 CCR3 −0.7764 C6orf129 −0.8042
PTTG1IP −0.8132 ROR1 −0.8005 SLC22A17 −0.8238 – −0.8144 PBX3 −0.7836 IQCG −0.8055
– −0.8211 PTS −0.82 POLL −0.8259 – −0.8277 – −0.7955 ZMYM6 −0.8146
– −0.8328 LDB1 −0.8301 RICS −0.8391 FKSG2 −0.8414 ADAMTS19 −0.7967 GBF1 −0.8296
– −0.8431 HYI −0.8304 BAAT −0.8581 PCDHGC3 −0.856 ABCG4 −0.8075 MED8 −0.8344
NRP2 −0.8713 FAS −0.8762 IRF2 −0.8639 – −0.8645 NDUFV3 −0.8178 MAP4K2 −0.863
PLCB2 −0.8824 C10orf11 −0.8832 KIAA1737 −0.8699 PRND −0.9166 ZNF564 −0.8301 – −0.877
–: Unknown gene.
r: Pearson correlation coefﬁcient.
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total RNA from the following 11 human cancer cell lines: YCC-B1
(breast cancer), HCT-116 (colon cancer), SK-HEP-1 (liver cancer), A549
(lung cancer), HL-60 (acute promyelocyte leukemia), MOLT-4 (acute
lymphoblastic leukemia), HeLa (cervical cancer), Caki-2 (kidney
cancer), T98G (glioblastoma), HT1080 (ﬁbrosarcoma) and YCC-3
(gastric cancer) [29]. The quantity and quality of RNA were conﬁrmed
by a ND-1000 spectrophotometer (NanoDrop Technologies, USA) and
gel electrophoresis.Oligonucleotide microarray
Oligonucleotidemicroarray analysis was performed using a human
oligo chip (CMRC-GT, Seoul, Korea) containing 22,740 oligonucleotide
probes of 70 bases with a reference design. The test samples (RNA
from each gastric cancer cell line) were labeled with Cy5 and
individually co-hybridized with the Cy3-labeled reference RNA
(CMRC, Seoul, Korea). For further analysis, raw Cy5/Cy3 data were
log2-transformed. Systemic errors were corrected by normalization
using intensity dependent, within-print, tip normalization based on
the Lowess function. After normalization, genes with more than one
missing value in all experiments were ﬁltered, no missing proportion
(NMP) 100%. The values of repeated genes were adjusted by S-Plus
2000 software (Insightful, Seattle, WA, USA). For the reliability of
experiments, YCC-10 was performed triplicate.Chemosensitivity assay
Growth inhibition was measured in 13 human gastric cancer cell
lines with 16 anticancer drugs (5-ﬂuorouracil, irinotecan, topotecan,
doxorubicin, etoposide, mitomycin, docetaxel, paclitaxel, cisplatin,
carboplatin, gemcitabine, vinblastine, vincristine, leucovorin, cyclopho-
sphamide and methotrexate,) provided by Yonsei Cancer Center (Seoul,
Korea) using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide, Sigma, Saint Louis, MO, USA) assay. The drug
concentration at which 50% of cancer cells survived (IC50, μM) was
calculated using Calcusyn software (Biosoft, Cambridge, UK). Since there
waswide variation in the scale of data points for different drugs, the IC50
was transformed into a log10 scale. Among the 16 anticancer drugs,
leucovorin and cyclophosphamide were used as a negative control
because leucovorin itself does not have any anti-tumor activity and
cyclophosphamide need in vivo activation for the anti-tumor activity.
GC-matrix analysis
The degree of similarity between the G-matrix and C-matrix was
calculated using the Pearson correlation coefﬁcient, r, calculated by
MATLAB software (The MathWorks, Inc) as follows:
r ¼ ∑ xi−xmð Þ yi−ymð Þﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑ xi−xmð Þ2 yi−ymð Þ2
q
Fig. 6. A schematic of the study design. a, signiﬁcance analysis of microarrays.
60 J.-J. Jung et al. / Genomics 93 (2009) 52–61Where xi denotes the log2 gene expression ratio (log2Cy5/Cy3) of
gene×in cell i, and yi denotes the log10 chemosensitivity (log10IC50) of
cell i to drug y. xm represents themean of the log2 gene expression ratio
of gene x, and ym represents the mean chemosensitivity of the drug.
Data analysis
A schematic of the study design is shown in Fig. 6. The gastric
cancer cell lines were divided into chemo-sensitive and chemo-
resistant groups based on the IC50 following the cut-off value of the
clinically achievable maximum concentration (Cmax, Supplementary
Table 2) of each drug. First, to identify the common chemosensitivity-
related genes, we selected the genes with a correlation coefﬁcient
greater than |0.40| in 11 of 16 anticancer drugs using GC-matrix. Next,
to identify the chemosensitivity-related genes for each speciﬁc drug,
the GC-matrix was used to select the genes with a correlation
coefﬁcient greater than |0.60| for each drug.We ﬁnally determined the
signiﬁcant genes which could divide the cell lines into chemo-
sensitive and -resistant groups using two-class signiﬁcance analysis of
microarrays (SAM) [30] with selected genes.
Hierarchical clustering analysis was performed with Cluster (Eisen
Lab, http://rana.lbl.gov/EisenSoftware.htm) and the resulting dendro-
gram was visualized using TreeView software (Eisen Lab). Clustering
was done by complete linkage algorithmwith uncentered correlation.
The distance of each cluster represents correlation between two
clusters. Multidimensional scaling (MDS) was done by using the BRB-
Arraytools version 3.3.0 software package (http://linus.nci.nih.gov/
BRB-ArrayTools.html) [31].
Annotation of the selected genes was performed using the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) (http://apps1.niaid.nih.gov/david) and the Stanford Online
Universal Resource for Clones and Expressed sequence tags (SOURCE)
(http://source.stanford.edu/cgi-bin/source/sourceSearch).
Quantitative RT-PCR
SOX9 and PTGER2 were randomly selected for validation of the
microarray data. Quantitative RT-PCR (qRT-PCR) was performed on 13gastric cancer cell lines. In brief, 4μg of total RNA from each sample was
reverse-transcribed using SuperScript II Reverse Transcriptase (Invitro-
gen, Carlsbad, CA, USA). Two hundred nanograms of synthesized cDNA
were PCR ampliﬁed using QuantiTect SYBR Green PCR (QIAGEN,
Valencia, CA, USA). Each reaction was run in duplicate on a Stratagene
MX3005P (Stratagene, La Jolla, CA,USA). Expression values for each gene
were determined using a standard curve constructed from Human
Genomic DNA (Promega, Madison, WI, USA). The house-keeping gene
ACTB was selected for normalization and the standard curve. Non-
template-control wells without cDNA were included as negative
controls. The primer sets for PCR ampliﬁcation were designed as
follows: SOX9-Sense: 5′-TTTCCAAGACACAAACATGA-3′, SOX9-Anti-
sense: 5′-AAAGTCCAGTTTCTCGTTGA-3′, PTGER2-Sense: 5′-GCTATCAT-
GACCATCACCTT-3′, PTGER2-Antisense: 5′-TGTGTTGCATCTTGTGTTCT-3′.
To compare gene expressions between microarray and qRT-PCR, we
calculated Pearson correlation coefﬁcient, and built a linear regression
model based on log2 ratio of real-time PCR.
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